TfR1 from Iron Metabolism to a Gateway for Brain Drug Delivery

Transferrin Receptor 1 (TfR1, also known as TFRC or CD71) has become one of the most important targets for delivering biologics across the blood-brain barrier (BBB). In this video, we explore the biology of TfR1, its role in iron transport and receptor-mediated transcytosis, and why it has emerged as a key platform for next-generation therapies targeting central nervous system (CNS) diseases. We also discuss Roche's Trontinemab, a TfR1 × amyloid-beta bispecific antibody that utilizes Brainshuttle™ technology to enhance brain delivery and improve treatment of Alzheimer's disease. In this video, you'll learn: What is Transferrin Receptor 1 (TfR1/CD71)? TfR1 structure and biological function How TfR1 transports iron across the blood-brain barrier TfR1-mediated transcytosis for CNS drug delivery Current landscape of TfR1-targeted therapeutics Roche's Trontinemab and Brainshuttle™ technology Research tools for TfR1 antibody discovery and characterization DIMA Biotechnology TfR1 Research Solutions DIMA Biotechnology provides comprehensive research tools for TfR1-targeted therapeutic development, including: • Recombinant TfR1 proteins from multiple species • Flow cytometry-validated anti-TfR1 antibodies • Biosimilar reference antibodies • Stable cell lines • In-stock anti-TfR1 recombinant antibodies for antibody discovery and engineering Whether you are developing bispecific antibodies, antibody-oligonucleotide conjugates, antibody-drug conjugates (ADCs), or other CNS therapeutics, our products are designed to accelerate your research. 📩 Contact us to learn more about our TfR1 research solutions and antibody discovery programs. 🌐 Website: https://www.dimabio.com #TfR1 #CD71 #BloodBrainBarrier #BBB #BrainDrugDelivery #Transcytosis #AlzheimersDisease #Trontinemab #BrainShuttle #BispecificAntibody #Neuroscience #Biologics #AntibodyDiscovery #DrugDiscovery #CNS #Biotechnology #DIMA Biotechnology